<DOC>
	<DOC>NCT02929719</DOC>
	<brief_summary>Therapeutic equivalence and safety study</brief_summary>
	<brief_title>Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris</brief_title>
	<detailed_description>To evaluate the therapeutic equivalence and safety of Test formulation and marketed Reference Listed Drug (RLD). To demonstrate the superiority of efficacy of the Test and Reference products over the placebo control in the treatment. To compare the safety of Test, Reference and Placebo treatments.</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Healthy male or non pregnant female aged ≥ 12 and ≤ 40years with a clinical diagnosis of acne vulgaris Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the Investigator's Global Assessment (IGA) (per Table 1 below) Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>